Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1806 results
September 2020
-
Speaking Up in CML
Lisa, a patient living with CML, shares her experience and discusses the importance of speaking up about unmet needs in your disease.
-
Media ReleaseNovartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit ScaleKisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score – confirming substantial benefit for premenopausal women with HR+/HER2- advanced…
-
Media ReleaseNovartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutationIn SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a…
-
Media ReleaseNovartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanomaBased on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 …
-
Featured NewsNovartis at ESMO
Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)
-
Media ReleaseNovartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJMCOMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1 Adjuvant…
-
Media ReleaseNovartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bondFirst healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access…
-
Featured NewsCommitted to increasing access
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
-
Media ReleaseEuropean Medicines Agency (EMA) approves safety label update for Novartis Beovu®Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal…
-
Bringing science and medicine together to help patients with cancer
Alice Shaw, Global Head of Translational Clinical Oncology at Novartis, applies lessons from running clinical trials to the work of designing them.
-
Media ReleaseNovartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1…
-
In The NewsProactive scenario planning and supply risk managementSteffen Lang, Global Head Novartis Technical Operations, on communication, data and automation during the COVID-19 crisis.
Pagination
- ‹ Previous page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- …
- 151
- › Next page